Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

EMA Recommends Granting a Conditional Marketing Authorisation for Dostarlimab

It is intended for the treatment of recurrent or advanced dMMR/MSI-H endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen
26 Feb 2021
Cancer Immunology and Immunotherapy;  Gynaecologic malignancies

On 25 February 2021, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product dostarlimab (Jemperli), intended for the treatment of certain types of recurrent or advanced endometrial cancer. 

The applicant for this medicinal product is GlaxoSmithKline (Ireland) Limited. 

Jemperli will be available as a solution for infusion (500 mg dostarlimab per 10 ml). The active substance of Jemperli is dostarlimab, an antineoplastic monoclonal antibody (ATC code: L01XC40) which potentiates T-cell responses, including anti-tumour responses through blockade of PD-1 binding to PD-L1 and PD-L2 ligands. 

The benefits with Jemperli are its effects on objective response rate and response duration in patients with mismatch repair deficient (dMMR) or with high microsatellite instability (MSI-H) recurrent or advanced endometrial cancer who have been previously treated. 

The most common side effects are anaemia, nausea, diarrhoea, vomiting, pruritus, rash, myalgia, pyrexia and hypothyroidism. 

The full indication is: 

Jemperli is indicated as monotherapy for the treatment of adult patients with recurrent or advanced dMMR/MSI-H endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen. 

Jemperli must be initiated and supervised by specialist physicians experienced in the treatment of cancer. 

Detailed recommendations for the use of this product will be described in the summary of product characteristics, which will be published in the European public assessment report and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission. 

Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion. 

A conditional marketing authorisation is granted to a medicinal product that fulfils an unmet medical need when the benefit to public health of immediate availability outweighs the risk inherent in the fact that additional data are still required. The marketing authorisation holder is expected to provide comprehensive clinical data at a later stage.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings